Please find enclosed
MEDICO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medico Remedies Ltd reported strong annual performance for FY 2025-26 with revenue from operations growing 36.8% to Rs. 20,637.73 lakhs from Rs. 15,094.06 lakhs in the previous year. Net profit after tax increased 30.1% to Rs. 1,312.52 lakhs compared to Rs. 1,009.32 lakhs in FY 2024-25. The company posted profit before tax of Rs. 1,805.96 lakhs, up from Rs. 1,350.37 lakhs. EBITDA margin showed slight compression to approximately 11.1% from 11.5% in the prior year. Operating cash flow remained positive at Rs. 587.42 lakhs. The statutory auditor changed mid-year from M/s V J Shah & Co to M/s Shah Shroff & Associates, who issued an unmodified (clean) audit opinion on the financial statements.
The company delivered robust double-digit growth in both revenue and profits, which is positive for shareholders. The clean audit opinion with no going concern issues adds credibility. However, slight EBITDA margin compression may attract some attention from investors focused on profitability efficiency.